Phase 2 Prostate Cancer Trial, Recruiting (NCT07285694)

Phase 2 Prostate Cancer Trial, Recruiting NCT07285694 Sponsor: Arsenal Biosciences, Inc. Condition: Prostate Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07285694 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Prostate Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be at least 18 years old at the time you sign the consent form
You have been diagnosed with prostate cancer (adenocarcinoma type) that has been confirmed by a tissue sample (biopsy)
Your prostate cancer has spread to other parts of the body (metastatic), is no longer responding to treatments that lower testosterone (castration-resistant), and has been getting worse according to specific medical guidelines
You have previously received at least one type of hormone-blocking treatment specifically targeting the androgen receptor (a protein that drives prostate cancer growth)
A special scan called a PSMA PET scan has shown that your cancer cells carry a specific marker called PSMA
Your cancer can be measured on scans, OR your PSA level (a prostate cancer marker in your blood) is at least 1 ng/mL
Your liver, kidneys, and other organs are working well enough to participate (confirm with trial site)

Who may not be able to join:

You have received any treatment for your castration-resistant prostate cancer within the 14 days before a scheduled blood cell collection procedure (called leukapheresis)
Your cancer has spread to the brain or spinal cord area, or is causing pressure on the spinal cord
You are not willing to take part in an extended period of safety check-ups after the trial treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 2 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07285694

Sponsor: Arsenal Biosciences, Inc.

Phase: Phase 2

Status: Recruiting

Condition: Prostate Cancer

More information: https://clinicaltrials.gov/study/NCT07285694

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be at least 18 years old at the time you sign the consent form
You have been diagnosed with prostate cancer (adenocarcinoma type) that has been confirmed by a tissue sample (biopsy)
Your prostate cancer has spread to other parts of the body (metastatic), is no longer responding to treatments that lower testosterone (castration-resistant), and has been getting worse according to specific medical guidelines
You have previously received at least one type of hormone-blocking treatment specifically targeting the androgen receptor (a protein that drives prostate cancer growth)
A special scan called a PSMA PET scan has shown that your cancer cells carry a specific marker called PSMA
Your cancer can be measured on scans, OR your PSA level (a prostate cancer marker in your blood) is at least 1 ng/mL
Your liver, kidneys, and other organs are working well enough to participate (confirm with trial site)

Who may not be able to join:

You have received any treatment for your castration-resistant prostate cancer within the 14 days before a scheduled blood cell collection procedure (called leukapheresis)
Your cancer has spread to the brain or spinal cord area, or is causing pressure on the spinal cord
You are not willing to take part in an extended period of safety check-ups after the trial treatment

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 2 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Arsenal Biosciences, Inc.

Registry

ClinicalTrials.gov

Start date

9 January 2026

Est. completion

1 May 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Safety and tolerability of AB-3028

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov